Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

Rotigotine, the active pharmaceutical ingredient, is a generic off-patent drug that is typically formulated as a once-daily transdermal patch to provide a slow and constant supply of the drug over the course of 24 hours.

The company claims it has optimized the dosage form efficiency to reduce the amount of drug required in each patch and improved overall patch adhesion to the patient's skin.

Vektor is now focused on process implementation for the manufacture of Rotigotine TDS clinical samples for use in human pilot studies. The parameters for increased manufacturing capacity are currently being evaluated with a final decision expected to be made within 30 days.

Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020.